Brief Title
Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy
Official Title
A Prospective Study of the Use of Micropulse 577nm Laser Treatment in Central Serous Chorioretinopathy
Brief Summary
The investigators hypothesis is that using the micropulse laser in patient with Central
Serous Chorioretinopathy (CSC) will prompt resolution of CSC and will be effective in
significantly minimizing visual recovery time from this disease as well as potentially
preventing recurrences.
Detailed Description
The investigators hypothesize that application of 577nm micropulse laser in patients with CSC
will prompt resolution of CSC as measured by ocular coherence tomography and best corrected
visual acuity. This will be a pilot study to establish sound methods and provide some
insights to the safety and efficacy of CSC treatment.
Study Type
Interventional
Primary Outcome
Resolution of Fluid Build-up
Condition
Central Serous Chorioretinopathy
Intervention
Micropulse Laser Treatment
Study Arms / Comparison Groups
Micropulse Laser Treatment
Description: Patient's randomized to ML treatment would be treated with the following settings: 200 micron spot size, 0.2 second duration, 15% duty cycle, and 300 milliWatt power. Their eyes would be dilated prior to treatment with standard mydriatic medications, including Tropicamide and Phenylephrine
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
2
Start Date
November 2012
Completion Date
November 2015
Primary Completion Date
November 2015
Eligibility Criteria
Inclusion Criteria:
- Patients with new diagnosis of CSC and no other comorbidities or prior retinal
treatment
- Patients ranging from 30 to 60 years of age
Exclusion Criteria:
- Patients with no case of CSC
- Patients with other macular comorbidities including but not limited to diabetic
retinopathy, macular degeneration
- Patients with prior retinal treatment
Gender
All
Ages
30 Years - 60 Years
Accepts Healthy Volunteers
No
Contacts
Jeevan Mathura, MD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT01982383
Organization ID
021236
Responsible Party
Sponsor
Study Sponsor
George Washington University
Study Sponsor
Jeevan Mathura, MD, Principal Investigator, George Washington University
Verification Date
March 2018